NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

NCT05363072

CompletedN/A

Sponsor: Pfizer

Conditions: Renal Cell Cancer, Renal Cell Carcinoma, Cancer of Kidney, Cancer of the Kidney, Kidney Cancer

Countries: Finland

The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

For the characteristic group:

* Diagnosis of renal cell carcinoma (International Classification of Diseases 10th revision \[ICD\]-10:64) during 01 January 2010 and 31 December 2021

For the mRCC group:

* ICD-10 diagnosis code for metastasis (C77\*-C79\*), or
* American Joint Committee on Cancer (AJCC) stage 4, or AJCC stage data potentially not available for all patients
* Visit to oncologist (specialty code 65) with RCC as main diagnosis, or In Finland, the ICD-10 codes for metastatic disease are rarely used. In contrast, RCC patients visit oncologist, when and only when disease metastasises and therefore, the visit can be used as a proxy to a metastatic disease
* Initiation of treatment for mRCC

Exclusion Criteria:

For the characteristic group:

* Prevalent mRCC patients (i.e. diagnosis of metastatic RCC before 01 January 2010)
* Prevalent mRCC patients (i.e. diagnosis of RCC before 01 January 2010) if there is no records of metastatic disease during 2010-2021

For the mRCC group:

* Prevalent patients with mRCC (i.e. diagnosis of metastatic RCC before 01 January 2010)
* Patients without treatment for mRCC

Locations (1)

Helsinki, Finland